Litcius/Paper detail

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial

Linda Stein Gold, Kim Papp, David M. Pariser, Lawrence Green, Neal Bhatia, Howard Sofen, Lorne Albrecht, Melinda Gooderham, Mindy Chen, Maria Paris, Yao Wang, Kristina Callis Duffin

2021Journal of the American Academy of Dermatology56 citationsDOI

Topics & Concepts

ApremilastMedicinePsoriasisPsoriasis Area and Severity IndexPlaceboClinical endpointAdverse effectBody surface areaInternal medicineDermatology Life Quality IndexNauseaRandomized controlled trialDermatologyPsoriatic arthritisPathologyAlternative medicinePsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsDermatology and Skin Diseases
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial | Litcius